

1. **A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival.**
Singh A, Greninger P, Rhodes DR, Koopman L, Violette S, Bardeesy N, Settleman J.
Cancer Cell. 2009 JUN 2;15(6):489-500.
2. **AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.**
Rhodes DR, Ateeq B, Cao Q, Tomlins SA, et al.
Proc Natl Acad Sci U S A. 2009 JUN 1.
3. **Exploring clinical associations using 'omics' based enrichment analyses.**
Hanauer DA, Rhodes DR, Chinnaiyan AM.
PLoS ONE. 2009;4(4):e5203.
4. **Coactivator Function Defines the Active Estrogen Receptor- α Cistrome.**
Lupien M, Eeckhoutte J, Meyer CA, Krum SA, Rhodes DR, Liu XS, Brown M.
Mol Cell Biol. 2009 APR 13.
5. **The role of SPINK1 in ETS rearrangement-negative prostate cancers.**
Tomlins SA, Rhodes DR, et al.
Cancer Cell. 2008 JUN;13(6):519-28.
6. **Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.**
Seitlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andr n O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, et al.
J Natl Cancer Inst. 2008 JUN 4;100(11):815-25.
7. **A polycomb repression signature in metastatic prostate cancer predicts cancer outcome.**
Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R, Wang X, Ghosh D, Shah RB, Varambally S, Pienta KJ, Chinnaiyan AM.
Cancer Res. 2007 NOV 15;67(22):10657-63.
8. **Identifying significant associations using free text problem summary lists in a clinical data repository.**
Hanauer DA, Rhodes DR, Chinnaiyan AM.
AMIA Annu Symp Proc. 2007 OCT 11:968. | 18694068
9. **Molecular concepts analysis links tumors, pathways, mechanisms, and drugs**
Rhodes DR, Kalyana-Sundaram S, Tomlins SA, et al.
Neoplasia 9 (5): 443-454 MAY 2007
10. **Integrating biomedical knowledge to model pathways of prostate cancer progression**
Morris DS, Tomlins SA, Rhodes DR, et al.
Cell Cycle 6 (10): 1177-1187 MAY 15 2007
11. **Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.**
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstett MJ, Kincaid-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM.
Neoplasia. 2007 FEB;9(2):166-80.
12. **Bioinformatics approaches in the study of cancer.**
Hanauer DA, Rhodes DR, Sinha-Kumar C, Chinnaiyan AM.
Curr Mol Med. 2007 FEB;7(1):133-41. Review.
13. **Integrative molecular concept modeling of prostate cancer progression.**
Scott A Tomlins, Rohit Mehra, Daniel R Rhodes, et al.
Nature Genetics 2007 JAN.; 39, 41 - 51
14. **Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.**
Giordano TJ, Au AYM, Quick R, Thomas DG, Rhodes DR, et al.
Clinical Cancer Research 2006 APR 1;12 (7 Pt 1):1983-93.
15. **TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.**
Tomlins SA, Mehra R, Rhodes DR, Smith LR, Roulston D, Helgeson BE, Cao X, Wei JT, Rubin MA, Shah RB, Chinnaiyan AM.
Cancer Res. 2006 APR 1;66(7):3396-400.
16. **Whole transcriptome amplification for gene expression profiling and development of molecular archives.**
Tomlins SA, Mehra R, Rhodes DR, Shah RB, Rubin MA, Bruening E, Makarov V, Chinnaiyan AM.
Neoplasia. 2006 FEB;8(2):153-62.
17. **Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.**
Fu Z, Kitagawa Y, Shen R, Shah R, Mehra R, Rhodes D, Keller PJ, Mizokami A, Dunn R, Chinnaiyan AM, Yao Z, Keller ET.
Prostate. 2006 FEB 15;66(3):248-56.
18. **Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.**
Varambally S, Yu JJ, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM.
Cancer Cell. 2005 NOV;8(5):393-406.
19. **Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.**
Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM.
Science 2005 OCT 28;310(5748):644-8.
20. **Probabilistic model of the human protein-protein interaction network.**
Rhodes DR, Tomlins SA, Varambally S, Mahavisno V, Barrette T, Kalyana-Sundaram S, Ghosh D, Pandey A, Chinnaiyan AM.
Nat Biotechnology. 2005 AUG; 23(8):951-9
21. **Integrative analysis of the cancer transcriptome.**
Rhodes DR, Chinnaiyan AM.
Nat Genet. 2005 JUN;37 Suppl:S31-7. Review.
22. **Mining for regulatory programs in the cancer transcriptome.**
Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM.
Nat Genet. 2005 JUN; 37(6):579-83.
23. **Large-Scale Meta-Analysis of Cancer Microarray Data Identifies Common Transcriptional Profiles of Neoplastic Transformation and Progression.**
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM.
PNAS 2004 JUN 22;101(25):9309-14.
24. **Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.**
Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, et al.
Cancer Res. 2004 JUN; 64 (11): 3814-3822
25. **Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers.**
Rhodes DR, Chinnaiyan AM.
Ann N Y Acad Sci. 2004 MAY;1020:32-40. Review.
26. **ONCOMINE: A Cancer Microarray Database and Data-Mining Platform.**
Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM.
Neoplasia 2004 JAN-FEB; 6(1):1-6
27. **Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.**
Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM.
J Natl Cancer Inst. 2004 JUN 2;96(11):834-43. Erratum in: *J Natl Cancer Inst*. 2004 JUL 21;96(14):1112.
28. **Prostate cancer biomarkers: a current perspective.**
Kumar-Sinha C, Rhodes DR, Yu J, Chinnaiyan AM.
Expert Rev Mol Diagn. 2003 JUL;3(4):459-70. Review.
29. **Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer.**
Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA.
J Natl Cancer Inst. 2003 MAY 7;95(9):661-8.
30. **Dysregulation of the annexin family protein family is associated with prostate cancer progression.**
Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA.
Am J Pathol. 2003 JAN;162(1):255-61.
31. **DNA microarrays: implications for clinical medicine.**
Rhodes DR, Chinnaiyan AM.
J Invest Surg. 2002 SEP-OCT;15(5):275-9. Review.
32. **Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer.**
Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM.
Cancer Res. 2002 AUG 1;62(15):4427-33.
33. **CIT: identification of differentially expressed clusters of genes from microarray data.**
Rhodes DR, Miller JC, Haab BB, Furge KA.
Bioinformatics. 2002 JAN;18(1):205-6.

1. **Identification of DOK genes as lung tumor suppressors.**
Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP.
Nat Genet. 2010 MAR;42(3):216-23. | 20139980
2. **Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.**
Erez N, Truitt M, Olson P, Hanahan D.
Cancer Cell. 2010 FEB 17;17(2):135-47. | 20138012
3. **The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.**
Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE.
Prostate. 2010 FEB 15;70(3):333-40. | 19790236
4. **Enhanced mRNA cap methylation increases cyclin D1 expression and promotes cell transformation.**
Cowling VH.
Oncogene. 2010 FEB 11;29(6):930-6. | 19915615
5. **Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung.**
Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II.
PLoS One. 2010 FEB 9;5(2):e9112. | 20161759
6. **Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.**
Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F.
Proc Natl Acad Sci USA. 2010 FEB 9;107(6):2616-21. | 20133782
7. **Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.**
Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, et al.
Blood. 2010 FEB 4;115(5):1006-17. | 19965641
8. **Mitotic chromosomal instability and cancer: mouse modelling of the human disease.**
Schvartzman JM, Sotillo R, Benezra R.
Nat Rev Cancer. 2010 FEB;10(2):102-15. | 20094045
9. **Emerging roles of deubiquitinases in cancer-associated pathways.**
Sacco JJ, Coulson JM, Clague MJ, Urbé S.
IUBMB Life. 2010 FEB;62(2):140-57. | 20073038
10. **A multiple-filter-multiple-wrapper approach to gene selection and microarray data classification.**
Leung Y, Hung Y.
IEEE/ACM Trans Comput Biol Bioinform. 2010 JAN;MAR;7(1):108-17. | 20150673
11. **Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth.**
Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ.
Mol Cell Biol. 2010 JAN;30(1):344-53. | 19858293
12. **Regulation of alphaB-crystallin gene expression by the transcription factor Ets1 in breast cancer.**
Bosman JD, Yehiely F, Evans JR, Cryns VL.
Breast Cancer Res Treat. 2010 JAN;119(1):63-70. | 19205872
13. **SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas.**
Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembelé D, Martinet N, Thibault C, Huelsen J, Brambilla E, du Manoir S.
PLoS One. 2010 JAN 29;5(1):e8960. | 20126410
14. **SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress.**
Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, et al.
Cancer Cell. 2010 JAN 19;17(1):41-52. | 20129246
15. **RalA suppresses early stages of Ras-induced squamous cell carcinoma progression.**
Sowalsky AG, Alt-Holland A, Shamis Y, Garlick JA, Feig LA.
Oncogene. 2010 JAN 7;29(1):45-55. | 19802010
16. **Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors.**
Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW.
J Immunol. 2010 JAN 15;184(2):702-12. | 20018620
17. **Global levels of histone modifications predict prostate cancer recurrence.**
Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gütgemann I, Walter B, Hofstädter F, Büttner R, Müller SC, Bastian PJ, von Ruecker A.
Prostate. 2010 JAN 1;70(1):61-9. | 19739128
18. **Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development.**
Thaker NG, Zhang F, McDonald PR, Shun TY, Lazo JS, Pollack IF.
Neurosurg Focus. 2010 JAN;28(1):E4. | 20043719
19. **Putative molecular signatures for the imaging of prostate cancer.**
Yang S Y, Adelstein J, Kassis AI.
Expert Rev Mol Diagn. 2010 JAN;10(1):65-74
20. **Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer.**
Prasad PD, Stanton JA, Assinder SJ.
Cell Tissue Res. 2010 Feb;339(2):337-47.
21. **Clusterin (CLU) and prostate cancer.**
Rizzi F, Bettuzzi S.
Adv Cancer Res. 2009;105:1-19. | 19879420
22. **Disease gene characterization through large-scale co-expression analysis.**
Day A, Dong J, Funari VA, Harry B, Strom SP, Cohn DH, Nelson SF.
PLoS One. 2009 DEC 31;4(12):e8491. | 20046828
23. **The helicase protein DHX29 promotes translation initiation, cell proliferation, and tumorigenesis.**
Parsyan A, Shahbazian D, Martineau Y, Petroulakis E, Alain T, Larsson O, Mathonnet G, Tettweiler G, Hellen CU, Pestova TV, Svitkin YV, Sonenberg N.
Proc Natl Acad Sci USA. 2009 DEC 29;106(52):22217-22. | 20018725
24. **Discovering collectively informative descriptors from high-throughput experiments.**
Jeffries CD, Ward WO, Perkins DO, Wright FA.
BMC Bioinformatics. 2009 DEC 18;10:431. | 20021653
25. **Tensin1 requires protein phosphatase-1alpha in addition to RhoGAP DLC-1 to control cell polarization, migration, and invasion.**
Hall EH, Daugherty AE, Choi CK, Horwitz AF, Brautigan DL.
J Biol Chem. 2009 DEC 11;284(50):34713-22. | 19826001
26. **Genetic inactivation of ApoJ/clusterin: effects on prostate tumorigenesis and metastatic spread.**
Bettuzzi S, Davalli P, Davoli S, Chayka O, Rizzi F, Belloni L, Pellacani D, Fregni G, Astancolle S, Fassan M, Corti A, Baffa R, Sala A.
Oncogene. 28, 4344-4352 (10 DEC 2009) | doi:10.1038/onc.2009.286
27. **The Sonic Hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts.**
Shaw A, Gipp J, Bushman W.
Oncogene. 2009 DEC 17;28(50):4480-90. | 19784071
28. **Housekeeping genes in prostate tumorigenesis.**
Byun J, Logothetis CJ, Gorlov IP.
Int J Cancer. 2009 DEC 1;125(11):2603-8. | 19551858
29. **Global repression of cancer gene expression in a zebrafish model of melanoma is linked to epigenetic regulation.**
Anelli V, Santoriello C, Distel M, Köster RW, Ciccarelli FD, Mione M.
Zebrafish. 2009 DEC;6(4):417-24. | 20047469
30. **Gene expression profiling of archival tongue squamous cell carcinomas provides sub-classification based on DNA repair genes.**
Rentoft M, Laurell G, Coates PJ, Sjöström B, Nylander K.
Int J Oncol. 2009 DEC;35(6):1321-30
31. **Translocations in epithelial cancers.**
Brenner JC, Chinnaiyan AM.
Biochim Biophys Acta. 2009 DEC;1796(2):201-15
32. **CRX is a diagnostic marker of retinal and pineal lineage tumors.**
Santagata S, Maire CL, Idbaih A, Geffers L, Correll M, Holton K, Quackenbush J, Ligon KL.
PLoS One. 2009 NOV 20;4(11):e7932. | 19936203

- 33. Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis.**
Unoki M, Brunet J, Mousli M.
Biochem Pharmacol. 2009 NOV 15;78(10):1279-88. | 19501055
- 34. Of the atypical PKCs, Par-4 and p62: recent understandings of the biology and pathology of a PB1-dominated complex.**
Moscat J, Diaz-Meco MT, Wooten MW.
Cell Death Differ. 2009 NOV;16(11):1426-37. | 19713972
- 35. Cross-platform method for identifying candidate network biomarkers for prostate cancer.**
Jin G, Zhou X, Cui K, Zhang XS, Chen L, Wong ST.
IET Syst Biol. 2009 NOV;3(6):505-12. | 19947776
- 36. Ncdin: a multi functional protein with potential tumor suppressor role?**
Chapman EJ, Knowles MA.
Mol Carcinog. 2009 NOV;48(11):975-81. | 19626646
- 37. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer.**
Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, Ponnala R, Cao X, Varambally S, Thomas DG, Giordano TJ, Beer DG, Palanisamy N, Sartor MA, Omenn GS, Chinnaiyan AM.
Nat Biotechnol. 2009 NOV;27(11):1005-11. | 19881495
- 38. Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion.**
Hu B, Thirumara-Rajamani KK, Sim H, Viapiano MS.
Mol Cancer Res. 2009 NOV;7(11):1756-70. | 19887559
- 39. The DEAD-box protein p72 regulates ERalpha-/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer.**
Wortham NC, Ahamed E, Nicol SM, Thomas RS, Periyasamy M, Jiang J, Ochocka AM, Shousha S, Huson L, Bray SE, Coombes RC, Ali S, Fuller-Pace FV.
Oncogene. 2009 NOV 19;28(46):4053-64. | 19718048
- 40. Correlating Global Gene Regulation to Angiogenesis in the Developing Chick Extra-Embryonic Vascular System.**
Javerzat S, Franco M, Herbert J, Platonova N, Peille AL, Pantesco V, De Vos J, Assou S, Bicknell R, Bikfalvi A, Hagedorn M.
PLoS One 2009 NOV 17;4(11):e7856
- 41. Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation.**
Devlin AH, Thompson P, Robson T, McKeown S.
Mol Carcinog 2009 NOV 11
- 42. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival.**
Pai VP, Marshall AM, Hernandez LL, Buckley AR, Horseman ND.
Breast Cancer Res 2009 NOV 10;11(6):R81
- 43. Multiple pathways in the FGF signaling network are frequently deregulated by gene amplification in oral dysplasias.**
Tsui IF, Poh CF, Garnis C, Rosin MP, Zhang L, Lam WL.
Int J Cancer 2009 NOV 1;125(9):2219-28
- 44. Atypical protein kinase C activity is required for extracellular matrix degradation and invasion by Src-transformed cells.**
Rodriguez EM, Dunham EE, Martin GS.
J Cell Physiol. 2009 OCT;221(1):171-82. | 19492416
- 45. Comprehensive Analysis of Conditioned Media from Ovarian Cancer Cell Lines Identifies Novel Candidate Markers of Epithelial Ovarian Cancer.**
Gunawardana CG, Kuk C, Smith CR, Batruch I, Soosaipillai A, Diamandis EP.
J Proteome Res 2009 OCT;8(10):4705-13
- 46. Identification of Tumor-associated Autoantigens for the Diagnosis of Colorectal Cancer in Serum Using High Density Protein Microarrays.**
Babel I, Barderas R, Díaz-Urriarte R, Martínez-Torrecuadrada JL, Sánchez-Carbayo M, Casal JI.
Mol Cell Proteomics 2009 OCT;8(10):2382-95
- 47. HAX-1: A multifunctional protein with emerging roles in human disease.**
Fadell B, Grzybowska E.
Biochim Biophys Acta 2009 OCT;1790(10):1139-48
- 48. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis.**
Fontemaggi G, Dell'Orso S, Trisciuglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, Del Bufalo D, Strano S, Blandino G.
Nat Struct Mol Biol 2009 OCT;16(10):1086-93
- 49. LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.**
Montañez-Wisovich ME, Seachrist DD, Landis MD, Visvader J, Andersen B, Keri RA.
Oncogene 2009 OCT 15;28(41):3608-18
- 50. Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.**
Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R.
Blood 2009 OCT 15;114(16):3361-2
- 51. A Role for the Clock Gene Per1 in Prostate Cancer.**
Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, Koeffler HP.
Cancer Res 2009 OCT 1;69(19):7619-25
- 52. Methylation-associated silencing of SFRP1 with an 8p11-12 amplification inhibits canonical and non-canonical WNT pathways in breast cancers.**
Yang ZQ, Liu G, Bollig-Fischer A, Haddad R, Tarca AL, Ethier SP.
Int J Cancer 2009 OCT 1;125(7):1613-21
- 53. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases.**
Vellaichamy A, Sreekumar A, Strahler JR, Rajendiran T, Yu J, Varambally S, Li Y, Omenn GS, Chinnaiyan AM, Nesvizhskii AI.
PLoS One. 2009 SEP 18;4(9):e7075. | 19763266
- 54. Gene networks in Drosophila melanogaster: integrating experimental data to predict gene function.**
Costello JC, Dalkilic MM, Beason SM, Gehlhausen JR, Patwardhan R, Middha S, Eads BD, Andrews JR.
Genome Biol 2009;10(9):R97
- 55. Unraveling the Signal-Transduction Networks in Cancer Metastasis.**
Guangxu Jin, Kemi Cui, Xiaobo Zhou, Wong S.
Signal Processing Magazine, IEEE 2009 SEP;26(5):129-132
- 56. Cancer attractors: A systems view of tumors from a gene network dynamics and developmental perspective.**
Huang S, Ernberg I, Kauffman S.
Semin Cell Dev Biol 2009 SEP;20(7):869-76
- 57. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.**
Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Barón AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL.
J Clin Invest 2009 SEP;119(9):2678-90 doi: 10.1172/JCI37815
- 58. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition.**
McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL.
J Clin Invest 2009 SEP;119(9):2663-77 doi: 10.1172/JCI37691
- 59. RHAMM (CD168) Is Overexpressed at the Protein Level and May Constitute an Immunogenic Antigen in Advanced Prostate Cancer Disease.**
Gust KM, Hofer MD, Perner SR, Kim R, Chinnaiyan AM, Varambally S, Moller P, Rinnab L, Rubin MA, Greiner J, Schmitt M, Kuefer R, Ringhoffer M.
Neoplasia 2009 SEP;11(9):956-63
- 60. Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor.**
Stylianou DC, Auf der Maur A, Kodack DP, Henke RT, Hohn S, Toretsky JA, Riegel AT, Wellstein A.
Oncogene 2009 SEP 17;28(37):3296-306
- 61. The IKK2/NF-kappa B pathway suppresses MYC-induced lymphomagenesis.**
Klaproth K, Sander S, Marinkovic D, Baumann B, Wirth T.
Blood 2009 SEP 17;114(12):2448-58
- 62. DNMT1 and DNMT3B Modulate Distinct Polycomb-Mediated Histone Modifications in Colon Cancer.**
Jin B, Yao B, Li JL, Fields CR, Delmas AL, Liu C, Robertson KD.
Cancer Res 2009 SEP 15;69(18):7412-21
- 63. Gene Expression Profile of Primary Prostate Epithelial and Stromal Cells in Response to Sulforaphane or Iberin Exposure.**
Chambers KF, Bacon JR, Kemsley EK, Mills RD, Ball RY, Mithen RF, Traka MH.
Prostate 2009 SEP 15;69(13):1411-21
- 64. Gene expression profiling of human alveolar macrophages infected by B. anthracis spores demonstrates TNF-alpha and NF-kappa b are key components of the innate immune response to the pathogen.**
Dozmorov M, Wu W, Chakrabarty K, Booth JL, Hurst RE, Coggeshall KM, Metcalf JP.
BMC Infect Dis 2009 SEP 10;9:152

- 65. Identification of a Protein, GOS2, That Lacks Bcl-2 Homology Domains and Interacts with and Antagonizes Bcl-2.** Welch C, Santra MK, El-Assaad W, Zhu X, Huber WE, Keys RA, Teodoro JG, Green MR. *Cancer Res* 2009 SEP 1;69(17):6782-9.
- 66. Biological determinants of endocrine resistance in breast cancer.** Musgrove EA, Sutherland RL. *Nat Rev Cancer*. 2009 SEP;9(9):631-43. | 19701242
- 67. A genomic perspective on vitamin D signaling.** Carlberg C, Seuter S. *Anticancer Res*. 2009 SEP;29(9):3485-93. | 19667142
- 68. Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System.** Kadara H, Lacroix L, Behrens C, Solis L, Gu X, Lee JJ, Tahara E, Lotan D, Hong WK, Wistuba II, Lotan R. *Cancer Prev Res (Phila Pa)* 2009 AUG;2(8):702-11
- 69. Transcriptional activation of the Lats1 tumor suppressor gene in tumors of CUX1 transgenic mice.** Siam R, Harada R, Cadieux C, Battat R, Vadnais C, Nepveu A. *Mol Cancer* 2009 AUG 5;8:60
- 70. Tumor Suppression by Phospholipase C-beta 3 via SHP-1-Mediated Dephosphorylation of Stat5.** Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kubagawa H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, Kawakami T. *Cancer Cell* 2009 AUG 4;16(2):161-71
- 71. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data.** Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efsthathiou E, Logothetis CJ. *BMC Med Genomics*. 2009 AUG 4;2:48. | 19653896
- 72. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.** Huang J, Wu S, Wu CL, Manning BD. *Cancer Res*. 2009 AUG 1;69(15):6107-14. | 19602587
- 73. Proteomic approaches in neuroblastoma: a complementary clinical platform for the future.** Kumar HR, Zhong X, Rescorla FJ, Hickey RJ, Malkas LH, Sandoval JA. *Expert Rev Proteomics*. 2009 AUG;6(4):387-94. | 19681674
- 74. Molecular predictors of response to a humanized anti-insulin-like growth factor-1 receptor monoclonal antibody in breast and colorectal cancer.** Zha J, O'Brien C, Savage H, Huw LY, Zhong F, Berry L, Lewis Phillips GD, Luis E, Cavet G, Hu X, Amler LC, Lackner MR. *Mol Cancer Ther*. 2009 AUG;8(8):2110-21. | 19671761
- 75. Oncomine meta-analysis of breast cancer microarray data identifies upregulation of NRF-1 expression in human breast carcinoma.** Kunkle B, Q. Felty, F. Trevino, D. Roy. *18th World IMACS / MODSIM Congress, Cairns, Australia 13-17 July 2009*
- 76. A c-Myc regulatory subnetwork from human transposable element sequences.** Wang J, Bowen NJ, Mariño-Ramírez L, Jordan IK. *Mol Biosyst*. 2009 DEC;5(12):1831-9. | 19763338
- 77. Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence.** Adam AP, George A, Schewe D, Bragado P, Iglesias BV, Ranganathan AC, Kourtidis A, Conklin DS, Aguirre-Ghiso JA. *Cancer Res*. 2009 JUL 15;69(14):5664-72. | 19584293
- 78. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer.** DiMeo TA, Anderson K, Phadke P, Feng C, Perou CM, Naber S, Kuperwasser C. *Cancer Res*. 2009 JUL 1;69(13):5364-73.
- 79. Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes.** Zhang M, Zhang L, Zou J, Yao C, Xiao H, Liu Q, Wang J, Wang D, Wang C, Guo Z. *Bioinformatics*. 2009 JUL 1;25(13):1662-8. | 19417058
- 80. Attenuated AMPA receptor expression allows glioblastoma cell survival in glutamate-rich environment.** van Vuurden DG, Yazdani M, Bosma I, Broekhuizen AJ, Postma TJ, Heimans JJ, van der Valk P, Aronica E, Tannous BA, Würdinger T, Kaspers GJ, Cloos J. *PLoS One*. 2009 JUN 18;4(6):e5953. | 19536293
- 81. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis.** Brennan SE, Kuwano Y, Alkharouf N, Blakeshear PJ, Garospe M, Wilson GM. *Cancer Res*. 2009 JUN 15;69(12):5168-76. | 19491267
- 82. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.** Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB, Paty PB, Rohle D, Vivanco I, Chmielecki J, Pao W, Ladanyi M, Gerald WL, Liu L, Cloughesy TC, Mischel PS, et al. *Proc Natl Acad Sci U S A*. 2009 JUN 9;106(23):9435-40.
- 83. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha.** Akaogi K, Nakajima Y, Ito I, Kawasaki S, Oie SH, Murayama A, Kimura K, Yanagisawa J. *Oncogene*. 2009 JUN 8.
- 84. Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancer.** Carey JP, Asirvatham AJ, Galm O, Ghogomu TA, Chaudhary J. *BMC Cancer*. 2009 JUN 7;9:173.
- 85. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors.** Hussain S, Zhang Y, Galardy PJ. *Cell Cycle*. 2009 JUN 1;8(11):1688-97.
- 86. Rab7 activation by growth factor withdrawal contributes to the induction of apoptosis.** Romero Rosales K, Peralta ER, Guenther GG, Wong SY, Edinger AL. *Mol Biol Cell*. 2009 JUN;20(12):2831-40.
- 87. Sam-pointed domain containing Ets transcription factor in luminal breast cancer pathogenesis.** Sood AK, Wang J, Mhawech-Fauceglia P, Jana B, Liang P, Gerads J. *Cancer Epidemiol Biomarkers Prev*. 2009 JUN;18(6):1899-903.
- 88. Heterochromatin protein 1alpha: a hallmark of cell proliferation relevant to clinical oncology.** De Koning L, Savignoni A, Boumendil C, Rehman H, Asselain B, Sastre-Garau X, Almouzni G. *EMBO Mol Med*. 2009 JUN;1(3):178-91. | 20049717
- 89. HtrA serine proteases as potential therapeutic targets in cancer.** Chien J, Campioni M, Shridhar V, Baldi A. *Curr Cancer Drug Targets*. 2009 JUN;9(4):451-68. | 19519315
- 90. Selenoprotein P regulation by the glucocorticoid receptor.** Rock C, Moos PJ. *Biometals*. 2009 JUN 10. | 19513589
- 91. Embryonic stem cell markers expression in cancers.** Schoenbals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. *Biochem Biophys Res Commun*. 2009 MAY 29;383(2):157-62.
- 92. Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen.** Rahrman EP, Collier LS, Knutson TP, Doyal ME, Kuslak SL, Green LE, Malinowski RL, Roethe L, Akagi K, Waknitz M, Huang W, Largaespada DA, Marker PC. *Cancer Res*. 2009 MAY 15;69(10):4388-97.
- 93. Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen.** Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA. *Clin Cancer Res*. 2009 MAY 15;15(10):3406-15. | 19401350
- 94. Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas.** Chayka O, Corvetta D, Dews M, Caccamo AE, Piotrowska I, Santilli G, Gibson S, Sebire NJ, Himoudi N, Hogarty MD, Anderson J, Bettuzzi S, Thomas-Tikhonenko A, Sala A. *J Natl Cancer Inst*. 2009 MAY 6;101(9):663-77.
- 95. B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells.** Mannefeld M, Klassen E, Gaubatz S. *Cancer Res*. 2009 MAY 1;69(9):4073-80.
- 96. Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer.** Wang R, Morris DS, Tomlins SA, Lonigro RJ, Tsodikov A, Mehra R, Giordano TJ, Kunju LP, Lee CT, Weizer AZ, Chinnaiyan AM. *Cancer Res*. 2009 MAY 1;69(9):3810-8. | 19383904
- 97. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.** Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM. *Prostate*. 2009 MAY 1;69(6):603-9. | 19125417

- 98. Proepithelin is an autocrine growth factor for bladder cancer.**
Lovat F, Bitto A, Xu SQ, Fassan M, Goldoni S, Metalli D, Wubah V, McCue P, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morriano A.
Carcinogenesis. 2009 MAY;30(5):861-8.
- 99. Artemin is oncogenic for human mammary carcinoma cells.**
Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX, Wu ZS, Zhu T, Liu DX, Lobie PE.
Oncogene. 2009 MAY 14;28(19):2034-45.
- 100. Quantitative proteomic analysis of follicular lymphoma cells in response to rituximab.**
Everton KL, Abbott DR, Crockett DK, Elenitoba-Johnson KS, Lim MS.
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 MAY 1;877(13):1335-43. | 19010092
- 101. A compendium of potential biomarkers of pancreatic cancer.**
Harsha HC, Kandasamy K, Ranganathan P, Rani S, Ramabadrans S, Gollapudi S, Balakrishnan L, Dwivedi SB, Telikicherla D, Selvan LD, Goel R, Mathivanan S, et al.
PLoS Med. 2009 APR 7;6(4):e1000046.
- 102. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.**
Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Chen H, Kong X, Melamed J, Fang S, Xiao Z, Veenstra TD, Qiu Y.
Cancer Cell. 2009 APR 7;15(4):270-82. | 19345326
- 103. Learning therapeutic lessons from metastasis suppressor proteins.**
Smith SC, Theodorescu D.
Nat Rev Cancer. 2009 APR;9(4):253-64.
- 104. Protein kinase C intervention: the state of play.**
Roffey J, Rosse C, Linch M, Hibbert A, McDonald NQ, Parker PJ.
Curr Opin Cell Biol. 2009 APR;21(2):268-79. | 19233632
- 105. Early gene expression changes during embryonic stem cell differentiation into cardiomyocytes and their modulation by monobutyl phthalate.**
van Dartel DA, Pennings JL, Hendriksen PJ, van Schooten FJ, Piersma AH.
Reprod Toxicol. 2009 APR;27(2):93-102. | 19162170
- 106. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer.**
Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, Gupta M, O'Sullivan MG, Matise J, Dupuy AJ, Collier LS, Powers S, Ober AL, Asmann YW, et al.
Science. 2009 MAR 27;323(5922):1747-50.
- 107. APRIL is overexpressed in cancer: link with tumor progression.**
Moreaux J, Veyrune JL, De Vos J, Klein B.
BMC Cancer. 2009 MAR 16;9:83.
- 108. Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation.**
Roidl A, Berger HJ, Kumar S, Bange J, Knyazev P, Ullrich A.
Clin Cancer Res. 2009 MAR 15;15(6):2058-66.
- 109. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.**
Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ.
PLoS One. 2009;4(3):e4710. | 19270750
- 110. Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth.**
Monami G, Emiliozzi V, Bitto A, Lovat F, Xu SQ, Goldoni S, Fassan M, Serrero G, Gomella LG, Baffa R, Iozzo RV, Morriano A.
Am J Pathol. 2009 MAR;174(3):1037-47. | 19179604
- 111. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors.**
Ojalvo LS, King W, Cox D, Pollard JW.
Am J Pathol. 2009 MAR;174(3):1048-64.
- 112. Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting ATRA-Induced Differentiation.**
Billottet, C; Banerjee, L; Vanhaesebroeck, B; Khwaja, A
Cancer Res. 2009 FEB 1;69(3):1027-36.
- 113. Gene expression profiling reveals overexpression of TSPAN13 in prostate cancer.**
Arencibia, JM; Martin, S; Perez-Rodriguez, FJ; Bonnin, A
Int J Oncol. 2009 FEB;34(2):457-63. 19148481
- 114. Oncogenic gene fusions in epithelial carcinomas.**
Prensner JR, Chinnaiyan AM.
Curr Opin Genet Dev. 2009 FEB;19(1):82-91. | 19233641
- 115. Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours.**
Sun R, Fu X, Li Y, Xie Y, Mao Y.
BMC Genomics. 2009 FEB 26;10:93. | 19245699
- 116. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.**
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, et al.
Nature. 2009 FEB 12;457(7231):910-4. | 19212411
- 117. Characterization of EVL-I as a protein kinase D substrate.**
Janssens, K; De Kimpe, L; Balsamo, M; Vandoninck, S; Vandenheede, JR; Gertler, F; Van Lint, J
Cell Signal. 2009 FEB;21(2):282-92.
- 118. Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2.**
Gordon KJ, Kirkbride KC, How T, Blobe GC.
Carcinogenesis. 2009 FEB;30(2):238-48. | 19056927
- 119. The Ral GTPase pathway in metastatic bladder cancer: Key mediator and therapeutic target.**
Smith, SC; Theodorescu, D
Urol Oncol. 2009 JAN-FEB;27(1):42-7.
- 120. Modulated expression of WFDC1 during carcinogenesis and cellular senescence.**
Madar, S; Brosh, R; Buganim, Y; Ezra, O; Goldstein, I; Solomon, H; Kogan, I; Goldfinger, N; Klocker, H; Rotter, V
Carcinogenesis. 2009 JAN;30(1):20-7.
- 121. DEK Proto-Oncogene Expression Interferes with the Normal Epithelial Differentiation Program.**
Wise-Draper, TM; Morreale, RJ; Morris, TA; Mintz-Cole, RA; Hoskii, EE; Balsitis, SJ; Husseinzadeh, N; Witte, DP; Wikenheiser-Brookamp, KA; Lambert, PF; Wells, SI
Am J Pathol. 2009 JAN;174(1):71-81.
- 122. AFAP120 regulates actin organization during neuronal differentiation.**
Xu X, Harder J, Flynn DC, Lanier LM.
Differentiation. 2009 JAN;77(1):38-47. | 19281763
- 123. Protein kinase Czeta represses the interleukin-6 promoter and impairs tumorigenesis in vivo.**
Galvez AS, Duran A, Linares JF, Pathrose P, Castilla EA, Abu-Baker S, Leitges M, Diaz-Meco MT, Moscat J.
Mol Cell Biol. 2009 JAN;29(1):104-15. | 18955501
- 124. Key signalling nodes in mammary gland development and cancer: Myc.**
Hynes NE, Stoelzle T.
Breast Cancer Res. 2009;11(5):210. | 19849814
- 125. Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest.**
Yang WS, Stockwell BR.
Genome Biol. 2008;9(6):R92. | 18518968
- 126. Does GATA3 act in tissue-specific pathways? A meta-analysis-based approach.**
Wilson BJ.
J Carcinog. 2008;7:6.
- 127. Molecular and prognostic markers in prostate cancer - A study of cell-cycle regulators, angiogenesis and candidate markers - Introduction.**
Halvorsen, DJ
APMIS Suppl. 2008;(123):5-62.
- 128. Arylamine N-acetyltransferases: From structure to function.**
Sim, E; Walters, K; Boukouvala, S
Drug Metab Rev. 2008;40(3):479-510.
- 129. MMSET is overexpressed in cancers: Link with tumor aggressiveness.**
Kassambara A, Klein B, Moreaux J.
Biochem Biophys Res Commun. 2008 DEC 30.
- 130. Transcriptome and proteome analyses of drug interactions with natural products.**
Fang H, Wang K, Zhang J.
Curr Drug Metab. 2008 DEC;9(10):1038-48. | 19075620
- 131. Confirmation of Gene Expression - Based Prediction of Survival in Non-Small Cell Lung Cancer.**
Guo, NL; Wan, YW; Tosun, K; Lin, H; Msiska, Z; Flynn, DC; Remick, SC; Vallyathan, V; Dowlati, A; Shi, X; Castranova, V; Beer, DG; Qian, Y
Clin Cancer Res. 2008 DEC 15;14(24):8213-20.
- 132. A stem cell gene expression profile of human squamous cell carcinomas.**
Jensen KB, Jones J, Watt FM.
Cancer Lett. 2008 DEC 8;272(1):23-31. | 18657901
- 133. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma.**
Tshukina, M; Jernberg-Wiklund, H; Nilsson, K; Oberig, F
Exp Hematol. 2008 DEC;36(12):1673-1681.
- 134. Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Pter4.**
Murn J, Alibert O, Wu N, Tendil S, Gidrol X.
J Exp Med. 2008 DEC 22;205(13):3091-103.

- 135. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.**
Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, Zielenska M, Soares FA, Squire JA.
Mod Pathol. 2008 DEC;21(12):1451-60. | 18500259
- 136. Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer.**
Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, Coetzee GA, Frenkel B.
Endocrinology. 2008 DEC;149(12):5984-95. | 18755791
- 137. A functional Notch-survivin gene signature in basal breast cancer.**
Lee CW, Simin K, Liu Q, Plescia J, Guha M, Khan A, Hsieh CC, Altieri DC.
Breast Cancer Res. 2008;10(6):R97.
- 138. Tissue Inhibitor of Metalloproteinases-4. The road less traveled.**
Melendez-Zajigla, J; Del Pozo, L; Ceballos, G; Maldonado, V
Mol Cancer. 2008 NOV 21;7:85.
- 139. Identifying differential correlation in gene/pathway combinations.**
Braun, R; Cope, L; Parmigiani, G
BMC Bioinformatics. 2008 NOV 18;9:488.
- 140. The Fbxw7/hCdc4 tumor suppressor in human cancer.**
Tan Y, Sangfelt O, Spruck C.
Cancer Lett. 2008 NOV 18;271(1):1-12. | 18541364
- 141. The Mitogen-Activated Protein Kinase Phosphatase Vaccinia H1-Related Protein Inhibits Apoptosis in Prostate Cancer Cells and Is Overexpressed in Prostate Cancer.**
Arnoldussen, YJ; Lorenzo, PI; Pretorius, ME; Waehre, H; Risberg, B; Maelandsmo, GM; Danielsen, HE; Saatcioglu, F
Cancer Res. 2008 NOV 15;68(22):9255-64.
- 142. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation.**
Perotti C, Liu R, Parusel CT, Böcher N, Schultz J, Bork P, Pfützer E, Groner B, Shemanko CS.
Breast Cancer Res. 2008;10(6):R94.
- 143. Integrative genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer.**
Yang Y, Iyer LK, Adelstein SJ, Kassis AI.
PLoS ONE. 2008;3(11):e3661.
- 144. DNA Hypomethylation Arises Later in Prostate Cancer Progression than CpG Island Hypermethylation and Contributes to Metastatic Tumor Heterogeneity.**
Yegnasubramanian, S; Haffner, MC; Zhang, YG; Gurel, B; Cornish, TC; Wu, ZJ; Irizarry, RA; Morgan, J; Hicks, J; DeWeese, TL; Isaacs, WB; Bova, GS; De Marzo, AM; Nelson, WG
Cancer Res. 2008 NOV 1;68(21):8954-67.
- 145. A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene.**
Gobeil S, Zhu X, Doillon CJ, Green MR.
Genes Dev. 2008 NOV 1;22(21):2932-40. | 18981472
- 146. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.**
Engelsen, IB; Stefansson, IM; Akslen, LA; Salvesen, HB
Am J Obstet Gynecol. 2008 NOV;199(5):543.e1-7.
- 147. Systematic identification and validation of candidate genes for detection of circulating tumor cells in peripheral blood specimens of colorectal cancer patients.**
Findeisen, P; Rockel, M; Nees, M; Roder, C; Kienle, P; Doeberitz, MW; Kalthoff, H; Neumaier, M
Int J Oncol. 2008 NOV;33(5):1001-10.
- 148. Notch1 is an effector of Akt and hypoxia in melanoma development.**
Bedogni, B; Warneke, JA; Nickloff, BJ; Giaccia, AJ; Powell, MB
J Clin Invest. 2008 Nov;118(11):3660-70. | 18924608
- 149. Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer.**
Varambally, S; Laxman, B; Mehra, R; Cao, Q; Dhanasekaran, S; Tomlins, SA; Granger, J; Vellaichamy, A; Sreekumar, A; Yu, JJ; Gu, WJ; Shen, RL; Ghosh, D; et al.
Neoplasia. 2008 NOV;10(11):1285-94. | 18953438
- 150. Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.**
Van Laere S, Beissbarth T, Van der Auwera I, Van den Eynden G, Trinh XB, Elst H, Van Hummelen P, van Dam P, Van Marck E, Vermeulen P, Dirix L.
Clin Cancer Res. 2008 NOV 15;14(22):7452-60.
- 151. The network biomarker discovery in prostate cancer from both genomics and proteomics levels.**
Jin GX, Zhou XB, Cui KM, et al.
Conference Information: 2nd International Symposium on Optimization and Systems Biology, OCT 31-NOV 03, 2008 Lijiang, PEOPLES R CHINA Volume: 9 Pages: 144-151 Published: 2008
- 152. FYN is overexpressed in human prostate cancer.**
Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ, Stadler WM, Rinker-Schaeffer C, Salgia R.
BJU Int. 2008 OCT 16.
- 153. The Polarity Protein Par6 Induces Cell Proliferation and Is Overexpressed in Breast Cancer.**
Nolan, ME; Aranda, V; Lee, S; Lakshmi, B; Basu, S; Allred, DC; Muthuswamy, SK
Cancer Res. 2008 OCT 15;68(20):8201-9.
- 154. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.**
Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, Cardiff RD, Cawaway KL 3rd, Sweeney C.
Cancer Res. 2008 OCT 15;68(20):8286-94. | 18922900
- 155. The correlation between cellular size and protein expression levels - Normalization for global protein profiling.**
Lundberg, E; Gry, M; Oksvold, P; Kononen, J; Andersson-Svahn, H; Ponten, F; Uhlen, M; Asplund, A
J Proteomics. 2008 OCT 7;71(4):448-60.
- 156. Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis.**
Kang, YK; Schiff, R; Ko, L; Wang, T; Tsai, SY; Tsai, MJ; O'Malley, BW
Cancer Res. 2008 OCT 1;68(19):7887-96.
- 157. Proteomic profiling of the effect of prostate-specific antigen on prostate cancer cells.**
Bindukumar B, Schwartz S, Aalinkeel R, Mahajan S, Lieberman A, Chadha K.
Prostate. 2008 OCT 1;68(14):1531-45. | 18646040
- 158. Copper & biological health.**
Krupanidhi S, Sreekumar A, Sanjeevi CB.
Indian J Med Res. 2008 OCT;128(4):448-61. | 19106440
- 159. A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma.**
Chaerkady R, Harsha HC, Nalli A, Gucek M, Vivekanandan P, Akhtar J, Cole RN, Simmers J, Schulick RD, Singh S, Torbenson M, Pandey A, Thuluvath PJ.
J Proteome Res. 2008 OCT;7(10):4289-98. | 18715028
- 160. Acid sphingomyelinase overexpression enhances the antineoplastic effects of irradiation in vitro and in vivo.**
Smith, EL; Schuchman, EH
Br J Cancer. 2008 SEP 16;99(6):939-48.
- 161. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.**
Kristiansen, G; Fritzsche, FR; Wassermann, K; Jager, C; Toelle, A; Lein, M; Stephan, C; Jung, K; Pilarsky, C; Dietel, M; Moch, H
Br J Cancer. 2008 SEP 16;99(6):939-48.
- 162. Akt regulation and lung cancer: a novel role and mechanism of action for the tumor suppressor Par-4.**
Diaz-Meco MT, Moscat J.
Cell Cycle. 2008 SEP 15;7(18):2817-20. | 18769154
- 163. Key Issues in Conducting a Meta-Analysis of Gene Expression Microarray Datasets.**
Ramasamy, A; Mondry, A; Holmes, CC; Altman, DG
PLoS Med. 2008 SEP 2;5(9):e184.
- 164. Loss of Raf kinase inhibitory protein induces radioresistance in prostate cancer.**
Woods Ignatoski KM, Grewal NK, Markwart SM, Vellaichamy A, Chinnaiyan AM, Yeung K, Ray ME, Keller ET.
Int J Radiat Oncol Biol Phys. 2008 SEP 1;72(1):153-60. | 18722266
- 165. Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment.**
Lange K, Kammerer M, Saupe F, Hegi ME, Grätge S, Fluri E, Orend G.
Cancer Res. 2008 SEP 1;68(17):6942-52. | 18757408
- 166. Studying chromosome instability in the mouse.**
Folijer, F; Draviam, VM; Sorger, PK
Biochim Biophys Acta. 2008 SEP;1786(1):73-82.
- 167. RCSI, a substrate of APC/C, controls the metaphase to anaphase transition.**
Zhao, WM; Coppinger, JA; Seki, A; Cheng, XL; Yates, JR; Fang, GW
Proc Natl Acad Sci U S A. 2008 SEP 9;105(36):13415-20.
- 168. Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer.**
Tseng-Rogenski SS, Arredouani MS, Neeley YC, Lu B, Chinnaiyan AM, Sanda MG.
Cancer Immunol Immunother. 2008, SEP;57(9):1357-65.
- 169. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.**
Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM.
Mod Pathol. 2008 SEP;21(9):1156-67. | 18567993

- 170. GATA-3 as a Marker of Hormone Response in Breast Cancer.**
Fang SH, Chen Y, Weigel RJ.
J Surg Res. 2008 AUG 26.
- 171. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.**
Han, YQ; Yang, L; Suarez-Saiz, F; San-Marina, S; Cui, J; Minden, MD
Mol Cancer Res. 2008 AUG;6(8):1347-55.
- 172. Membrane-associated phospholipase A1 beta (LIPI) is an Ewing tumour-associated cancer/testis antigen.**
Foell, JL; Hesse, M; Volkmer, I; Schmiedel, BJ; Neumann, I; Staeger, MS
Pediatr Blood Cancer. 2008 AUG;51(2):228-34.
- 173. Meta-analysis of SUMO1.**
Wilson BJ.
BMC Res Notes. 2008 JUL 31;1:60.
- 174. ATF6 alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo.**
Schewe, DM; Aguirre-Ghiso, JA
Proc Natl Acad Sci U S A. 2008 JUL 29;105(30):10519-24.
- 175. The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis.**
Frohlich, DA; McCabe, MT; Arnold, RS; Day, ML
Oncogene. 2008 JUL 17;27(31):4353-62.
- 176. Acetylcholinesterase supports anchorage independence in colon cancer.**
Syed, M; Fenoglio-Preiser, C; Skau, KA; Weber, GF
Clin Exp Metastasis. 2008;25(7):787-98.
- 177. Recurrent gene fusions in prostate cancer.**
Kumar-Sinha C, Tomlins SA, Chinnaiyan AM.
Nat Rev Cancer. 2008 JUL;8(7):497-511.
- 178. Pathway analysis reveals functional convergence of gene expression profiles in breast cancer.**
Shen R, Chinnaiyan AM, Ghosh D.
BMC Med Genomics. 2008 JUN 27;1:28. | 18588682
- 179. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer.**
Grady WM, Parkin RK, Mitchell PS, Lee JH, Kim YH, Tsuchiya KD, Washington MK, Paraskova C, Willson JK, Kaz AM, Kroh EM, Allen A, Fritz BR, Markowitz SD, Tewari M.
Oncogene. 2008 JUN 19;27(27):3880-8. | 18264139
- 180. Targeting the BAF57 SWI/SNF subunit in prostate cancer: A novel platform to control androgen receptor activity.**
Link, KA; Balasubramanian, S; Sharma, A; Comstock, CES; Godoy-Tundidor, S; Powers, N; Cao, KH; Haelens, A; Claes-sens, F; Revelo, MP; Knudsen, KE
Cancer Res. 2008 JUN 15;68(12):4551-8.
- 181. Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation.**
Ghosh D, Chinnaiyan AM.
Biostatistics. 2008 JUN 6.
- 182. Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway.**
Wilson BJ, Giguère V.
Mol Cancer. 2008 JUN 4;7:49.
- 183. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene.**
Ganesan, K; Ivanova, T; Wu, YH; Rajasegaran, V; Wu, J; Lee, MH; Yu, K; Rha, SY; Chung, HC; Ylstra, B; Meijer, G; Lian, KO; Grabsch, H; Tan, P
Cancer Res. 2008 JUN 1;68(11):4277-86.
- 184. Data-driven Networking Reveals 5-Genes Signature for Early Detection of Lung Cancer**
Vladimir Kuznetsov, V; Thomas, S; Bonchev, D.
2008 International Conference on BioMedical Engineering and Informatics; MAY 27-30
- 185. Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis.**
Chan, TA; Glackner, S; Yi, JM; Chen, W; Van Neste, L; Cope, L; Herman, JG; Velculescu, V; Schuebel, KE; Ahuja, N; Baylín, SB
PLoS Med. 2008 MAY 27;5(5):e114.
- 186. Re: Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.**
Lusa, L; Peissel, B; Manoukian, S; Marchesi, E; Radice, P; Pierotti, MA; Gariboldi, M
J Natl Cancer Inst. 2008 MAY 21;100(10):752-3; author reply 753-4.
- 187. A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the human NBPF1 and ACCN1 genes.**
Vandepoel K, Andries V, Van Roy N, Staes K, Vandesompele J, Laureys G, De Smet E, Bexx G, Speleman F, van Roy F.
PLoS One. 2008 MAY 21;3(5):e2207. | 18493581
- 188. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.**
Mehra R, Tomlins SA, Yu J, Cao X, Wang L, Menon A, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.
Cancer Res. 2008 MAY 15;68(10):3584-90.
- 189. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer.**
Meyer, KB; Maia, AT; O'Reilly, M; Teschendorff, AE; Chin, SF; Caldas, C; Ponder, BAJ
PLoS Biol. 2008 MAY 6;6(5):e108.
- 190. The discovery and application of gene fusions in prostate cancer.**
Morris DS, Tomlins SA, Montie JE, Chinnaiyan AM.
BJU Int. 2008 APR 16.
- 191. Elevated tRNA(i)(Met) synthesis can drive cell proliferation and oncogenic transformation.**
Marshall, L; Kenneth, NS; White, RJ
Cell. 2008 APR 4;133(1):78-89.
- 192. Amplification and overexpression of PPF1A1, a putative Ilq13 invasion suppressor gene, in head and neck squamous cell carcinoma.**
Tan, KD; Zhu, Y; Tan, HK; Rajasegaran, V; Aggarwal, A; Wu, J; Wu, HY; Hwang, J; Lim, DTH; Soo, KC; Tan, P
Genes Chromosomes Cancer. 2008 APR;47(4):353-62.
- 193. Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics**
Sellar, G; Alvarez, JD; Loganzo, F; Abbas, R; Immermann, F; Karnoub, M; Feuerstein, GZ; Burczynski, ME; Coughlin, CM
Biomarkers in Medicine April 2008, Vol. 2, No. 2, Pgs 147-153
- 194. The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.**
Butt, AJ; Sergio, CM; Inman, CK; Anderson, LR; McNeil, CM; Russell, AJ; Nusch, M; Preiss, T; Biankin, AV; Sutherland, RL; Musgrove, EA
Breast Cancer Res. 2008;10(2):R28.
- 195. Predicting cancer involvement of genes from heterogeneous data.**
Aragues, R; Sander, C; Oliva, B
BMC Bioinformatics. 2008 MAR 27;9:172.
- 196. TM4SF3 promotes esophageal carcinoma metastasis via upregulating ADAM12m expression.**
Zhou, Z; Ran, YL; Hu, H; Pan, J; Li, ZF; Chen, LZ; Sun, LC; Peng, L; Zhao, XL; Yu, L; Sun, LX; Yang, ZH
Clin Exp Metastasis. 2008;25(5):537-48.
- 197. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer.**
McCabe, CD; Spyropoulos, DD; Martin, D; Moreno, CS
Cancer Res. 2008 MAR 15;68(6):1988-96.
- 198. Tumor cell dependence on Ran-GTP-directed mitosis.**
Xia, F; Lee, CW; Altieri, DC
Cancer Res. 2008 MAR 15;68(6):1826-33.
- 199. Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates.**
Li, RS; Guo, Y; Han, BM; Yan, XW; Utleg, AG; Li, W; Tu, LC; Wang, J; Hood, L; Xia, SJ; Lin, BY
Proteomics. 2008 MAR 7;2(4):543-555
- 200. p73 poses a barrier to malignant transformation by limiting anchorage-independent growth.**
Beitzinger, M; Hofmann, L; Oswald, C; Beinoraviciute-Kellner, R; Sauer, M; Griesmann, H; Bretz, AC; Burek, C; Rosenwald, A; Stiewe, T
EMBO J. 2008 MAR 5;27(5):792-803.
- 201. Gene expression profiling of non-small-cell lung cancer.**
Lacroix, L; Commo, F; Soria, JC
Expert Rev Mol Diagn. 2008 Mar;8(2):167-78.
- 202. CXCL5 promotes prostate cancer progression.**
Begley LA, Kasina S, Mehra R, Adsule S, Admon AJ, Lonigro RJ, Chinnaiyan AM, Macoska JA.
Neoplasia. 2008 MAR;10(3):244-54.
- 203. Humoral response profiling reveals pathways to prostate cancer progression.**
Taylor BS, Pal M, Yu J, Laxman B, Kalyana-Sundaram S, Zhao R, Menon A, Wei JT, Nesvizhskii AI, Ghosh D, Omenn GS, Lubman DM, Chinnaiyan AM, Sreekumar A.
Mol Cell Proteomics. 2008 MAR;7(3):600-11.
- 204. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers.**
Chan SK, Griffith OL, Tai IT, Jones SJ.
Cancer Epidemiol Biomarkers Prev. 2008 MAR;17(3):543-52. | 18349271
- 205. Hsp60 regulation of tumor cell apoptosis.**
Ghosh, JC; Dohi, T; Kang, BH; Altieri, DC
J Biol Chem. 2008 FEB 22;283(8):5188-94.

- 206. Ubiquitination by TOPORS regulates the prostate tumor suppressor NKX3.1.**
Guan B, Pungalaya P, Li X, Uquillas C, Mutton LN, Rubin EH, Bieberich CJ.
J Biol Chem. 2008 FEB 22;283(8):4834-40. | 18077445
- 207. Phosphorylation of Skp2 regulated by CDK2 and Cdc14B protects it from degradation by APC(Cdh1) in G1 phase.**
Rodier G, Coulombe P, Tanguay PL, Boutonnet C, Meloche S.
EMBO J. 2008 FEB 20;27(4):679-91. | 18239684
- 208. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.**
Sorensen, KD; Borre, M; Orntoft, TF; Dyrskjot, L; Torring, N
Int J Cancer. 2008 FEB 1;122(3):509-19.
- 209. Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways.**
Ruiz-Vela, A; Aggarwal, M; de la Cueva, P; Treda, C; Her-
reros, B; Martfn-Perez, D; Dominguez, O; Piris, MA
Blood. 2008 FEB 1;111(3):1665-76.
- 210. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.**
Laxman B, Morris DS, Yu J, Siddiqui J, Cao J, Mehra R, Lonigro RJ, Tsodikov A, Wei JT, Tomlins SA, Chinnaiyan AM.
Cancer Res. 2008 FEB 1;68(3):645-9.
- 211. CD200: a putative therapeutic target in cancer.**
Moreaux J, Veyrone JL, Reme T, De Vos J, Klein B.
Biochem Biophys Res Commun. 2008 FEB 1;366(1):117-22.
- 212. Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression.**
Gordon, KJ; Dong, M; Chislock, EM; Fields, TA; Blobe, GC
Carcinogenesis. 2008 FEB;29(2):252-62.
- 213. CLEAR-test: Combining inference for differential expression and variability in microarray data analysis.**
Valls, J; Grau, M; Sole, X; Hernandez, P; Montaner, D; Dopazo, J; Peinado, MA; Capella, G; Moreno, V; Pujana, MA
J Biomed Inform. 2008 FEB;41(1):33-45.
- 214. Role of the TMPRSS2-ERG gene fusion in prostate cancer.**
Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, Helgeson BE, Cao Q, Prensner JR, Rubin MA, Shah RB, Mehra R, Chinnaiyan AM.
Neoplasia. 2008 FEB;10(2):177-88.
- 215. Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.**
Smith DD, Saetrom P, Snove O Jr, Lundberg C, Rivas GE, Glackin C, Larson GP.
BMC Bioinformatics. 2008 JAN 28;9(1):63
- 216. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.**
Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM.
Cancer Res. 2008 JAN 1;68(1):73-80.
- 217. A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival.**
Chinnaiyan, AM; Lippman, ME; Yu, JJ; Yu, J; Cordero, KE; Johnson, MD; Ghosh, D; Rae, JM
Neoplasia. 2008 JAN;10(1):79-88.
- 218. Pathway analysis tools and toxicogenomics reference databases for risk assessment.**
Ganter B, Zidek N, Hewitt PR, Müller D, Vladimirova A.
Pharmacogenomics. 2008 JAN;9(1):35-54. | 18154447
- 219. DLG1 is an anchor for the E3 ligase MARCH2 at sites of cell-cell contact.**
Cao, ZF; Huett, A; Kuballa, P; Giallourakis, C; Xavier, RJ
Cell Signal. 2008 JAN;20(1):73-82.
- 220. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer.**
Wong, SY; Crowley, D; Bronson, RT; Hynes, RO
Clin Exp Metastasis. 2008;25(2):109-18.
- 221. Transcriptional profiling of inductive mesenchyme to identify molecules involved in prostate development and disease.**
Vanpoucke, G; Orr, B; Grace, OC; Chan, R; Ashley, GR; Williams, K; Franco, OE; Hayward, S; Thomson, AA
Genome Biol. 2007;8(10):R213.
- 222. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.**
Blenkiron, C; Goldstein, LD; Thorne, NP; Spiteri, I; Chin, SF; Dunning, MJ; Barbosa-Morais, NL; Teschendorff, AE; Green, AR; Ellis, IO; Tavare, S; Caldas, C; Miska, EA
Genome Biol. 2007;8(10):R214.
- 223. High-resolution array comparative genomic hybridization of chromosome 8q: evaluation of putative progression markers for gastroesophageal junction adenocarcinomas.**
van Duijn, M; van Marion, R; Vissers, KJ; Hop, WCJ; Dinjens, WNM; Tilanus, HW; Siersema, PD; van Dekken, H
Cytogenet Genome Res. 2007;118(2-4):130-7.
- 224. A role for glial cell-derived neurotrophic factor-induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer.**
Essegir, S; Todd, SK; Hunt, T; Poulsom, R; Plaza-Menacho, I; Reis-Filho, JS; Isacke, CM
Cancer Res. 2007 DEC 15;67(24):11732-41.
- 225. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer.**
Xiang, Y; Zhu, Z; Han, G; Ye, X; Xu, B; Peng, Z; Ma, Y; Yu, Y; Lin, H; Chen, AP; Chen, CD
Proc Natl Acad Sci U S A. 2007 DEC 4;104(49):19226-31.
- 226. A mechanism misregulating p27 in tumors discovered in a functional genomic screen.**
Garrett-Engele, CM; Tasch, MA; Hwang, HC; Fero, ML; Perlmutter, RM; Clurman, BE; Roberts, JM
PLoS Genet. 2007 DEC;3(12):e219.
- 227. Selective Raf inhibition in cancer therapy.**
Khazak V, Astaturov I, Serebriiskii IG, Golemis EA.
Expert Opin Ther Targets. 2007 DEC;11(12):1587-609. | 18020980
- 228. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor.**
Dubovsky JA, McNeel DG.
Prostate. 2007 DEC 1;67(16):1781-90. | 17929270
- 229. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.**
Wu, MH; Soler, DR; Abba, MC; Nunez, MI; Baer, R; Hatzis, C; Llobat-Cussac, A; Llobat-Bosch, A; Aldaz, CM
Mol Cancer Res. 2007 DEC;5(12):1285-95.
- 230. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin.**
Leong, KG; Niessen, K; Kulic, I; Raouf, A; Eaves, C; Pollet, I; Karson, A
J Exp Med. 2007 NOV 26;204(12):2935-48.
- 231. Transforming growth factor-beta receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?**
Sharif, N; Lechleider, RJ; Farrar, WL
J Mol Endocrinol. 2007 NOV;39(5):329-32.
- 232. Identification of novel pathway partners of p68 and p72 RNA helicases through Oncome meta-analysis.**
Wilson BJ, Giguère V.
BMC Genomics. 2007 NOV 15;8:419.
- 233. Heat shock protein B8, a cyclin-dependent kinase-independent cyclin D1 target gene, contributes to its effects on radiation sensitivity.**
Trent S, Yang C, Li C, Lynch M, Schmidt EV.
Cancer Res. 2007 NOV 15;67(22):10774-81. | 18006821
- 234. Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer.**
Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins SA, Creighton CJ, Dhanasekaran SM, Shen R, Chen G, Morris DS, Marquez VE, Shah RB, Ghosh D, Varambally S, Chinnaiyan AM.
Cancer Cell. 2007 NOV;12(5):419-31.
- 235. Understanding systemic sclerosis through gene expression profiling.**
Pendergrass, SA; Whitfield, ML; Gardner, H
Curr Opin Rheumatol. 2007 NOV;19(6):561-7.
- 236. Meta- and gene set analysis of stomach cancer gene expression data.**
Kim, S; Kim, J; Lee, H; Noh, S; Song, K; Cho, J; Jeong, H; Kim, WH; Yeom, Y; Kim, N; Kim, S; Yoo, H; Kim, YS
Mol Cells. 2007 OCT 31;24(2):200-9.
- 237. Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion.**
Darwiche, N; Ryscavage, A; Perez-Lorenzo, R; Wright, L; Bae, DS; Hennings, H; Yuspa, SH; Glick, AB
Oncogene. 2007 OCT 18;26(48):6885-95.
- 238. JMJD3 is a histone H3K27 demethylase.**
Xiang, Y; Zhu, ZQ; Han, G; Lin, HQ; Xu, LY; Chen, CD
Cell Res. 2007 OCT;17(10):850-7.
- 239. Claudin-7 immunohistochemistry in renal tumors - A candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.**
Hornsby, CD; Cohen, C; Amin, MB; Picken, MM; Lawson, D; Yin-Goen, QQ; Young, AN
Arch Pathol Lab Med. 2007 OCT;131(10):1541-6.
- 240. A latent variable approach for meta-analysis of gene expression data from multiple microarray experiments.**
Choi H, Shen R, Chinnaiyan AM, Ghosh D.
BMC Bioinformatics. 2007 SEP 27;8:364.

- 241. Identification of five human novel genes associated with cell proliferation by cell-based screening from an expressed cDNA ORF library.**
Ma, X; Wang, X; Gao, X; Wang, L; Lu, Y; Gao, P; Deng, WW; Yu, P; Ma, JJ; Guo, JH; Cheng, HL; Zhang, CY; Shi, TP; Ma, DL
Life Sci. 2007 SEP 15;81(14):1141-51.
- 242. Integrative analysis of genomic aberrations associated with prostate cancer progression.**
Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, Ghosh D, Shedden K, Montie JE, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM.
Cancer Res. 2007 SEP 1;67(17):8229-39.
- 243. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.**
Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, Shen R, Montie JE, Chinnaiyan AM, Shah RB.
Cancer Res. 2007 SEP 1;67(17):7991-5.
- 244. Thymosin beta-NB is the human isoform of rat thymosin beta 15.**
Banyard, J; Hutchinson, LM; Zetter, BR
Ann N Y Acad Sci. 2007 SEP;1112:286-96.
- 245. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.**
Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M.
Mol Cell. 2007 AUG 3;27(3):380-92.
- 246. Cellular functions of 14-3-3zeta in apoptosis and cell adhesion emphasize its oncogenic character.**
Niemantsverdriet M, Wagner K, Visser M, Backendorf C.
Oncogene. 2008 FEB 21;27(9):1315-9.
- 247. Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior.**
Degen M, Brellier F, Kain R, et al.
Cancer Research 67 (19): 9169-9179 OCT 1 2007
- 248. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status.**
Abba MC, Sun H, Hawkins KA, et al.
Molecular Cancer Research 5 (9): 881-890 SEP 2007
- 249. Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer.**
Zhang L, Huang J, Yang N, et al.
Clinical Cancer Research 13 (18): 5314-5321 Part 1 SEP 15 2007
- 250. The Ia autoantigen is a malignancy-associated cell death target that is induced by DNA-damaging drugs.**
Al-Ejeh F, Darby JM, Brown MP
Clinical Cancer Research 13 (18): 5509s-5518s Part 2 Suppl. S SEP 15 2007
- 251. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.**
Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, Yu J, Wang L, Montie JE, Rubin MA, Pienta KJ, Roulston D, Shah RB, Varambally S, Mehra R, Chinnaiyan AM.
Nature. 2007 AUG 2;448(7153):595-9.
- 252. The lethal phenotype of cancer: the molecular basis of death due to malignancy.**
Loberg RD, Bradley DA, Tomlins SA, Chinnaiyan AM, Pienta KJ.
CA Cancer J Clin. 2007 JUL-AUG;57(4):225-41. Review.
Erratum in: *CA Cancer J Clin.* 2007 NOV-DEC;57(6):380.
- 253. UTRN on chromosome 6q24 is mutated in multiple tumors.**
Li Y, Huang J, Zhao YL, et al.
Oncogene 26 (42): 6220-6228 SEP 13 2007
- 254. Expression of interleukin-13 receptor alpha 2 in glioblastoma multiforme: Implications for targeted therapies.**
Jarboe JS, Johnson KR, Choi Y, et al.
Cancer Research 67 (17): 7983-7986 SEP 1 2007
- 255. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth.**
O'Neill CF, Urs S, Cinelli C, et al.
American Journal of Pathology 171 (3): 1023-1036 SEP 2007
- 256. Mining gene expression profiles: expression signatures as cancer phenotypes.**
Joseph R. Nevins and Anil Potti
Nature Reviews/Genetics. 2007 AUG vol 8:601
- 257. Protein 4.1B suppresses prostate cancer progression and metastasis.**
Wong SY, Haack H, Kissil JL, et al.
Proceedings of The National Academy of Sciences of The United States of America 104 (31): 12784-12789 JUL 31 2007
- 258. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.**
Wang QB, Li W, Liu XS, et al.
Molecular Cell 27 (3): 380-392 AUG 3 2007
- 259. The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition.**
Tedesco D, Zhang JH, Trinh L, et al.
Neoplasia 9 (7): 601-u4 JUL 2007
- 260. Pre- and post-initiation chemoprevention activity of 2-alkyl/aryl selenazolidine-4(R)-carboxylic acids against tobacco-derived nitrosamine (NNK)-induced lung tumors in the A/J mouse.**
Franklin MR, Moos PJ, El-Sayed WM, et al.
Chemico-Biological Interactions 168 (3): 211-220 JUL 20 2007
- 261. Evidence for systems-level molecular mechanisms of tumorigenesis.**
Hernandez P, Huerta-Cepas J, Montaner D, et al.
BMC Genomics 8: Art. No. 185 JUN 20 2007
- 262. Expression of Ral GTPases, their effectors, and activators in human bladder cancer.**
Smith SC, Oxford G, Baras AS, et al.
Clinical Cancer Research 13 (13): 3803-3813 JUL 1 2007
- 263. Large-scale integration of cancer microarray data identifies a robust common cancer signature.**
Xu L, Geman D, Winslow RL
BMC Bioinformatics 8: Art. No. 275 JUL 30 2007
- 264. Characterization of protein-interaction networks in tumors.**
Platzer A, Perco P, Lukas A, et al.
BMC Bioinformatics 8: Art. No. 224 JUN 27 2007
- 265. Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer.**
Paulson KE, Rieger-Christ K, McDevitt NA, et al.
Cancer Research 67 (13): 6136-6145 JUL 1 2007
- 266. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization.**
Lange K, Kammerer M, Hegi ME, et al.
Cancer Research 67 (13): 6163-6173 JUL 1 2007
- 267. Metastasis-associated protein 1 transgenic mice: A new model of spontaneous B-Cell lymphomas.**
Bagheri-Yarmand R, Balasenthil S, Gururaj AE, et al.
Cancer Research 67 (15): 7062-7067 AUG 1 2007
- 268. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data.**
Kim B, Lee HJ, Choi HY, et al.
Cancer Research 67 (15): 7431-7438 AUG 1 2007
- 269. DGEM - A Microarray gene expression database for primary human disease tissues.**
Xia YN, Campen A, Riggsby D, et al.
Molecular Diagnosis & Therapy 11 (3): 145-149 2007
- 270. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.**
Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA.
Am J Surg Pathol. 2007 JUN;31(6):882-8.
- 271. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.**
Mosquera JM, Perner S, Demichelis F, Kim R, Hofer MD, Mertz KD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, Rubin MA.
J Pathol. 2007 MAY;212(1):91-101.
- 272. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes.**
Warnat P, Oberthuer A, Fischer M, et al.
BMC Cancer 7: Art. No. 89 MAY 25 2007
- 273. CKAP2 is a spindle-associated protein degraded by APC/C-cdh1 during mitotic exit.**
Seki A, Fang GW
Journal of Biological Chemistry 282 (20): 15103-15113 MAY 18 2007
- 274. Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34.**
Abba MC, Fabris VT, Hu YH, et al.
Cancer Research 67 (9): 4104-4112 MAY 1 2007
- 275. Graph-based identification of cancer signaling pathways from published gene expression signatures using PubLiME.**
Finocchiaro G, Mancuso FM, Cittaro D, et al.
Nucleic Acids Research 35 (7): 2343-2355 APR 2007
- 276. CCR2 expression correlates with prostate cancer progression.**
Lu Y, Cai Z, Xiao GZ, et al.
Jrl of Cellular Biochemistry 101 (3): 676-685 JUN 1 2007
- 277. Mass spectrometry-based "omics" technologies in cancer diagnostics.**
Zhang XW, Wei D, Yap Y, et al.
Mass Spectrometry Rvws 26 (3): 403-431 MAY-JUN 2007
- 278. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis.**
Ma WB, Stafford LJ, Li DL, et al.
Jrl of Cellular Biochemistry 100 (6): 1376-1386 APR 15 2007

- 279. Autoantibody profiles reveal ubiquitin 1 as a humoral immune response target in lung adenocarcinoma.**
Chen GA, Wang XJ, Yu JJ, et al.
Cancer Research 67 (7): 3461-3467 APR 1 2007
- 280. 5-aza-2'-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer.**
Zorn CS, Wojno KJ, McCabe MT, et al.
Clinical Cancer Research 13 (7): 2136-2143 APR 1 2007
- 281. Feature selection and molecular classification of cancer using genetic programming.**
Yu JJ, Yu JD, Almal AA, et al.
Neoplasia 9 (4): 292-U16 APR 2007
- 282. Role of the chromobox protein CBX7 in lymphomagenesis.**
Scott CL, Gil J, Hernando E, et al.
Proceedings of The National Academy of Sciences of The United States of America 104 (13): 5389-5394 MAR 27 2007
- 283. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer.**
Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, Wei JT, Pienta KJ, Ghosh D, Rubin MA, Chinnaiyan AM, Shah RB.
Mod Pathol. 2007 MAY;20(5):538-44.
- 284. Bone morphogenic protein antagonist Dnm/gremlin is a novel proangiogenic factor.**
Stabile H, Mitola S, Moroni E, et al.
Blood 109 (5): 1834-1840 MAR 1 2007
- 285. LRIG-inhibitors of growth factor signalling - double-edged swords in human cancer?**
Hedman H, Henriksson R
European Journal of Cancer 43 (4): 676-682 MAR 2007
- 286. Identification of functional cell adhesion molecules with a potential role in metastasis by a combination of in vivo phage display and in silico analysis.**
Sadanandam A, Varney ML, Kinarsky L, et al.
Omic's-A Jnl of Integrative Biology 11 (1): 41-57 MAR 2007
- 287. Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1.**
Rody A, Holtrich U, Gaetje R, et al.
Clinical Cancer Research 13 (4): 1115-1122 FEB 15 2007
- 288. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.**
Podar K, Raab MS, Tonon G, et al.
Cancer Research 67 (4): 1680-1688 FEB 15 2007
- 289. Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion.**
Lin KY, Lu D, Hung CF, et al.
Cancer Research 67 (4): 1832-1841 FEB 15 2007
- 290. TGFB3 loss and consequences in prostate cancer.**
Sharifi N, Hurt EM, Kawasaki BT, et al.
Prostate 67 (3): 301-311 FEB 15 2007
- 291. DNA microarray technology in toxicogenomics of aquatic models: Methods and applications.**
Ju ZL, Wells MC, Walter RB
Comparative Biochemistry & Physiology C-toxicology & Pharmacology 145 (1): 5-14 Sp. Iss. SI FEB 2007
- 292. From bytes to bedside: Data integration and computational biology for translational cancer research.**
Mathew JP, Taylor BS, Bader GD, et al.
PLoS Computational Biology 3 (2): 153-163 FEB 2007
- 293. KLF4 suppresses transformation of pre-B cells by ABL oncogenes.**
Kharas, MG; Yusuf, I; Scarfone, VM; Yang, VW; Segre, JA; Huettner, CS; Fruman, DA
Blood. 2007 JAN 15;109(2):747-55.
- 294. A novel nuclear interactor of ARF and MDM2 (NIAM) that maintains chromosomal stability.**
Tompkins, VS; Hagen, J; Frazier, AA; Lushnikova, T; Fitzgerald, MP; di Tommaso, A; Ladeveze, V; Domann, FE; Eischen, CM; Quelle, DE
J Biol Chem. 2007 JAN 12;282(2):1322-33.
- 295. Chromosomal deletions in bladder cancer: Shutting down pathways.**
Abraham R, Pagano F, Gomella LG, et al.
Frontiers In Bioscience 12: 826-838 JAN 1 2007
- 296. Innovation - The Connectivity Map: a new tool for biomedical research.**
Lamb, J
Nat Rev Cancer. 2007 JAN;7(1):54-60. | 17186018
- 297. Computational prediction of cancer-gene function.**
Hu, ZP; Bader, G; Wigle, DA; Emili, A
Nature Reviews/Cancer. 2007 JAN; vol 7:23
- 298. Mad2 overexpression promotes aneuploidy and tumorigenesis in mice.**
Sotillo R, Hernando E, Diaz-Rodriguez E, et al.
Cancer Cell 11 (1): 9-23 JAN 2007
- 299. Targeting cell cycle kinases for cancer therapy.**
de Cancer G, de Castro IP, Malumbres M
Current Medicinal Chemistry 14 (9): 969-985 2007
- 300. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas.**
Assou S, Le Carrouer T, Tondeur S, et al.
Stem Cells 25 (4): 961-973 2007
- 301. Loss of Nrpd1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.**
Yen L, Cao ZW, Wu XL, et al.
Cancer Research 2006 DEC; 66 (23): 11279-11286.
- 302. Resources for integrative systems biology: From data through databases to networks and dynamic system models.**
Ng A, Bursteinas B, Gao QO, et al.
Briefings in Bioinformatics 2006 DEC; 7 (4): 318-330.
- 303. Positional expression profiling indicates candidate genes in deletion hotspots of hepatocellular carcinoma.**
Chan KYY, Lai PBS, Squire JA, et al.
Modern Pathology 2006 DEC; 19 (12): 1546-1554.
- 304. Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cells.**
Molinaro, RJ; Jha, BK; Malathi, K; Varambally, S; Chinnaiyan, AM; Silverman, RH
Nucleic Acids Res. 2006;34(22):6684-95.
- 305. The HBP1 transcriptional repressor participates in RAS-induced premature senescence.**
Zhang XW, Kim J, Ruthazer R, et al.
Molecular an Cellular Biology 2006.; 26 (22): 8252-8266.
- 306. A Novel Role of Myosin VI in Human Prostate Cancer.**
Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, Ewing CM, Sauvageot J, Isaacs WB, De Marzo AM, Luo J.
American J Pathology. 2006 NOV; 169(5):1843-54.
- 307. Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer.**
Rubin MA, Chinnaiyan AM.
Laboratory Investigation 2006 NOV; 86 (11): 1099-1102.
- 308. Evidence of recurrent gene fusions in common epithelial tumors.**
Kumar-Sinha C, Tomlins SA, Chinnaiyan AM
Trends in Molecular Medicine 2006 NOV; 12 (11): 529-536.
- 309. Strategies for plasma proteomic profiling of cancers.**
Omenn, GS
Proteomics. 2006 OCT;6(20):5662-73.
- 310. Comparative microarray analysis.**
Larsson O, Wennmalm K, Sandberg R
Omic's-A Journal of Integrative Biology 2006 SEP; 10 (3): 381-397.
- 311. Cep55, a microtubule-bundling protein, associates with centralspindlin to control the midbody integrity and cell abscission during cytokinesis.**
Zhao WM, Seki A, Fang GW.
Molecular Biology of the Cell 2006 SEP; 17 (9): 3881-3896.
- 312. Differential proteomic alterations between localized and metastatic prostate cancer.**
Taylor BS, Varambally S, Chinnaiyan AM.
British Journal of Cancer 2006 AUG; 95 (4): 425-430.
- 313. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.**
Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K.
Nature. 2006 JUL 20;442(7100):307-11.
- 314. Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue.**
Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G, Rubin MA.
Arch Pathol Lab Med. 2006 JUL;130(7):989-96.
- 315. CCL2 is a potent regulator of prostate cancer cell migration and proliferation.**
Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neeley CK, Pienta KJ.
Neoplasia. 2006 JUL; 8(7):578-86.
- 316. Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma.**
Guo L, Ma Y, Ward R, Castranova V, Shi X, Qian Y.
Clinical Cancer Res. 2006 JUN 1;12(11 Pt 1):3344-54.
- 317. Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism.**
Kim SW, Mangold U, Waghorne C, Mobascher A, Shantz L, Banyard J, Zetter BR.
J Cell Science. 2006 JUN 15;119(Pt 12):2583-91.
- 318. Identical probes on different high-density oligonucleotide microarrays can produce different measurements of gene expression.**
Zhang L, Yoder SJ, Enkemann SA.
BMC Genomics 2006 JUN; 7: Art. No. 153.

- 319. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.**
Yoshimoto M, Joshua AM, Chilton-Macneil S, Bayani J, Selvarajah S, Evans AJ, Zielenska M, Squire JA. *Neoplasia*. 2006 JUN;8(6):465-9.
- 320. Identification of genes expressed differentially in an in vitro human lung carcinogenesis model.**
Lacroix L, Feng G, Lotan R. *Cancer Biology & Therapy* 2006 JUN; 5 (6): 665-673.
- 321. Cross-platform classification in microarray-based leukemia diagnostics.**
Nilsson B, Andersson A, Johansson M, Fioretos T. *Haematologica*. 2006 JUN;91(6):821-4.
- 322. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.**
Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. *J Clin Invest*. 2006 JUN;116(6):1582-95.
- 323. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.**
Collard RL, Harya NS, Monzon FA, Maier CE, O'Keefe DS. *Prostate*. 2006 MAY 15;66(7):687-95.
- 324. Integrative genomic analysis of protein kinase C (PKC) family identifies PKC α as a biomarker and potential oncogene in ovarian carcinoma.**
Zhang L, Huang J, Yang N, Liang S, Barchetti A, Giannakakis A, Cadungog MG, O'Brien-Jenkins A, Massobrio M, Roby KF, Katsaros D, Gimotty P, Butzow R, Weber BL, Coukos G. *Cancer Res*. 2006 MAY 1;66(9):4627-35.
- 325. Functional screening for proapoptotic genes by reverse transfection cell array technology.**
Mannherz O, Mertens D, Hahn M, Lichter P. *Genomics*. 2006 MAY;87(5):665-72.
- 326. Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene.**
Li Z, Szabolcs M, Terwilliger JD, Efstratiadis A. *Carcinogenesis*. 2006 MAY;27(5):1054-67.
- 327. Prostate-specific antigen, high-molecular-weight cytokeratin (Clone 34 beta E12), and/or p63 - An optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.**
Kunju LP, Mehra R, Snyder M, Shah RB. *Am J Clin Pathol*. 2006 MAY;125(5):675-81.
- 328. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease.**
Kuefer R, Day KC, Kleer CG, Sabe MS, Hofer MD, Varambally S, Zorn CS, Chinnaiyan AM, Rubin MA, Day ML. *Neoplasia*. 2006 APR;8(4):319-29.
- 329. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.**
Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, Wallace M, Hagen J, Quelle DE, Watson MA, Perry A, Gutmann DH, Ratner N. *Cancer Res*. 66, 2584-2591, MAR 1, 2006.
- 330. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis.**
O'Donnell KA, Yu DN, Zeller KI, Kim JW, Racke F, Thomas-Tikhonenko A, Dang CV. *Mol Cell Biol*. 2006 MAR;26(6):2373-86.
- 331. ETS-TMPRSS2 fusion gene products in prostate cancer.**
Ahlers CM, Figg WD. *Cancer Biol Ther*. 2006 MAR;5(3):254-5.
- 332. Low pH induces co-ordinate regulation of gene expression in oesophageal cells.**
Duggan SP, Gallagher WM, Fox EJ, Abdel-Latif MM, Reynolds JV, Kelleher D. *Carcinogenesis*. 2006 FEB;27(2):319-27.
- 333. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer.**
Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, Tindall DJ, Young CY. *Clinical Cancer Res*. 2006 FEB 15;12(4):1128-36.
- 334. Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients.**
Henrich KO, Fischer M, Mertens D, Benner A, Wiedemeyer R, Brors B, Oberthuer A, Berthold F, Wei JS, Khan J, Schwab M, Westermann F. *Clinical Cancer Res*. 2006 JAN 1;12(1):131-8.
- 335. Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.**
Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V, Oren M. *Oncogene*. 2006 JAN 19;25(3):359-69.
- 336. Defining aggressive prostate cancer using a 12-gene model.**
Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, Hofer MD, Febbo PG, Chinnaiyan AM, Rubin MA. *Neoplasia*. 2006 JAN;8(1):59-68.
- 337. Molecular markers for discrimination of benign and malignant follicular thyroid tumors.**
Fryknas M, Wickenberg-Bolin U, Goransson H, Gustafsson MG, Foukakis T, Lee JJ, Landegren U, Hoog A, Larsson C, Grimelius L, Wallin G, Pettersson U, Isaksson A. *Tumor Biol*. 2006;27(4):211-20.
- 338. Integrative biology of prostate cancer progression.**
Tomlins SA, Rubin MA, Chinnaiyan AM. *Annual Review of Pathology-Mechanisms of Disease* 1 (1): 243-271 2006.
- 339. Molecular analysis of minimally invasive follicular carcinomas by gene profiling.**
Lubitz CC, Gallagher LA, Finley DJ, Zhu B, Fahey TJ. *Surgery*. 2005 DEC;138(6):1042-8.
- 340. A review of the past, present, and future directions of neoplasia.**
Rehemtulla A, Ross BD. *Neoplasia* 2005 DEC; 7(12), 1039-1046.
- 341. The octamer binding transcription factor Oct-1 is a stress sensor.**
Tantini D, Schild-Poulter C, Wang V, Hache RJ, Sharp PA. *Cancer Res*. 2005 DEC 1;65(23):10750-8.
- 342. Two different global gene expression profiles in cancer cell lines established from etiologically different oral carcinomas.**
Rutu M, Johansson B, Grenman R, Syrjanen S. *Oncol Rep* 2005 DEC; 14(6), 1511-1517.
- 343. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.**
Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG. *Cancer Res*. 2005 DEC 15; 65(24):11259-64.
- 344. The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells.**
Zeidler M, Varambally S, Cao Q, Chinnaiyan AM, Ferguson DO, Merajver SD, Kleer CG. *Neoplasia* 2005 DEC. 7(11), 1011-1019.
- 345. Overlapping gene expression in fetal mouse intestine development and human colorectal cancer.**
Hu M, Shivdasani RA. *Cancer Res*. 2005 OCT 1;65(19):8715-22.
- 346. Identification of MMP-15 as an anti-apoptotic factor in cancer cells.**
Abraham R, Schafer J, Rothe M, Bange J, Knyazev P, Ullrich A. *J Biol Chem*. 2005 OCT 7;280(40):34123-32.
- 347. List of lists-annotated (LOLA): a database for annotation and comparison of published microarray gene lists.**
Cahan P, Ahmad AM, Burke H, Fu S, La, Y, Florea L, Dharker N, Kobriniski T, Kale P, McCaffrey TA. *Gene* 2005 OCT; 360, 78-82.
- 348. Mechanisms of PECAM-1-mediated cytoprotection and implications for cancer cell survival.**
Bergom C, Gao C, Newman PJ. *Leuk Lymphoma*. 2005 OCT; 46(10):1409-21.
- 349. Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data.**
Xu L, Tan AC, Naiman DQ, Geman D, Winslow RL. *Bioinformatics* 2005 OCT; 21, 3905-3911.
- 350. Autoantibody signatures in prostate cancer.**
Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giachero D, Mehra R, Montie JE, Pienta KJ, Sanda MG, Kantoff PW, Rubin MA, Wei JT, Ghosh D, Chinnaiyan AM. *NEJM*. 2005 SEP; (2): 1224-1235.
- 351. Prostate cancer cells promote osteoblastic bone metastases through Wnts.**
Hall CL, Baifco A, Dai J, Aaronson SA, Keller ET. *Cancer Res*. 2005 SEP 1;65(17):7554-60.
- 352. Functional profiling: from microarrays via cell-based assays to novel tumor relevant modulators of the cell cycle.**
Arlt D, Huber W, Liebel U, Schmidt C, Majety M, Saueremann M, Rosenfelder H, Bechtel S, Mehrle A, Bannasch D, Schupp I, Seiler M, Simpson JC, Hahne F, Moosmayer P, Ruschhaupt M, Guillaume B, Wellenreuther R, Pepperkok R, Sultmann H, Poustka A, Wiemann S. *Cancer Res*. 2005 SEP; 65(17):7733-42.
- 353. Emerging issues of the expression profiling technologies for the study of gynecologic cancer.**
Pappa KI, Anagnou NP. *Am J Obstet Gynecol* 2005 SEP.; 193, 908-918.
- 354. TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas.**
Kleivi K, Diep CB, Pandis N, Heim S, Teixeira MR, Lothe RA. *J Pathol*. 2005 SEP; 207(1):14-9.

- 355. Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker?**
Hashimoto Y, Skacel M, Adams JC.
Int J Biochem Cell Biol 2005 SEP; 37, 1787-1804.
- 356. From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response.**
Laganieri J, Deblois G, Lefebvre C, Bataille AR, Robert F, Giguere V.
Proc Natl Acad Sci USA 2005 AUG; 102,11651-11656.
- 357. GEMS: a system for automated cancer diagnosis and biomarker discovery from microarray gene expression data.**
Statnikov A, Tsamardinos, I, Dosbayev Y, Aliferis CF.
Int J Med Inform 2005 AUG; 74, 491-503.
- 358. Storing, linking, and mining microarray databases using SRS.**
Veldhoven A, de Lange D, Smid M, de Jager V, Kors JA, Jenster G.
BMC Bioinformatics 2005 JUL; 6, 192.
- 359. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals.**
Alpy F, Tomasetto C.
J Cell Science 2005 JUL; 118, 2791-2801.
- 360. High-resolution genomic profiles of human lung cancer.**
Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatri DB, Protopopov A, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Depinho RA.
Proc Natl Acad Sci U S A. 2005 JUL; 102(27):9625-30.
- 361. Microarray-based classification of diffuse large B-cell lymphoma.**
Poulsen CB, Borup R, Nielsen FC, Borregaard N, Hansen M, Gronbaek K, Moller MB, Ralfkiaer E.
European J Haematology. 2005 JUN; 74(6):453-65.
- 362. A genetic screen for candidate tumor suppressors identifies REST.**
Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, et al.
Cell 2005 JUN; 121, 837-848.
- 363. Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers.**
Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Olson S, Gonzalez A, Carbone DP, Dang TP.
Cancer Research 2005 MAY; 65, 3555-3561.
- 364. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification.**
Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D, Leenders F, Claude JC, Theuring F, Bargou R, et al.
Cancer Research 2005 MAY; 65, 4078-4087.
- 365. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.**
Mayer GL, Kung WJ, Martinez A, Izumiya C, Chen DJ, Kung HJ.
J Biol Chem 2005 MAR; 280, 10827-10833.
- 366. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.**
Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R.
Cancer Research. 2005 FEB 15; 65(4):1479-88.
- 367. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential.**
Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orłowska-Volk M, Bauknecht T, Park TW, Jonat W, Jacobsen A, Sehoul J, Luttgies J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM.
Oncogene. 2005 FEB 3;24(6):1053-65.
- 368. Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty.**
Dhanasekaran SM, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA, Creighton CJ, Menon A, Rubin MA, Chinnaiyan AM.
FASEB J. 2005 FEB;19(2):243-5.
- 369. A database for tracking toxicogenomic samples and procedures.**
Bao, W; Schmid, JE; Goetz, AK; Ren, H; Dix, DJ.
Reproductive Toxicology 2005 JAN.-FEB.; 19, 411-419.
- 370. L2L: a simple tool for discovering the hidden significance in microarray expression data.**
Newman, JC; Weiner, AM.
Genome Biol 2005. 6(9), R81.
- 371. Common and contrasting genomic profiles among the major human lung cancer subtypes.**
Tonon G, Brennan C, Protopopov A, Maulik G, Feng B, Zhang Y, Khatri DB, You MJ, Aguirre AJ, Martin ES, Yang Z, Ji H, Chin L, Wong KK, DePinho RA.
Cold Spring Harb Symp Quant Biol. 2005;70:11-24. | 16869734
- 372. The tumor protein D52 family: many pieces, many puzzles.**
Boutros R, Fanayan S, Shehata M, Byrne JA.
Biochem Biophys Res Commun 2004 DEC; 325, 1115-1121.
- 373. Splicing factors are differentially expressed in tumors.**
Kirschbaum-Slager N, Lopes GM, Galante PA, Riggins GJ, de Souza SJ.
Genet Mol Res. 2004 DEC 30;3(4):512-20.
- 374. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program.**
Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ.
Cancer Res. 2004 DEC; 64(24):9209-16.
- 375. QA/QC: challenges and pitfalls facing the microarray community and regulatory agencies.**
Shi L, Tong W, Goodsaid F, Frueh FW, Fang H, Han T, Fuscoe J, Casciano DA.
Expert Rev Mol Diagnostics 2004 NOV; 4, 761-777.
- 376. Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells.**
Guzey M, Luo J, Getzenberg RH.
J Cell Biochem. 2004 OCT 1;93(2):271-85.
- 377. JAGGED1 expression is associated with prostate cancer metastasis and recurrence.**
Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC.
Cancer Res. 2004 OCT; 64(19):6854-7.
- 378. Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin.**
Wagner KW, Sapinoso LM, El-Rifai W, Frierson HF, Butz N, Mestan J, Hofmann F, Devereaux QL, Hampton GM.
Oncogene 2004 AUG; 23 (39): 6621-6629.
- 379. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors.**
Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H.
Hum Mol Genet. 2004 JUL;13(13):1303-13.
- 380. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck.**
Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, Pambuccian SE, Ondrey FG, Adams GL, Gaffney PM.
Cancer Res. 2004 JAN 1;64(1):55-63.